Question Title

* 1. How significantly will CNPV influence your organization's planning for regulatory submission strategies, aiming for the accelerated 1–2 month review?

Question Title

* 2. How likely is your organization to invest in new US facility capacity specifically to increase the chances of qualifying for accelerated FDA review?

Question Title

* 3. How transparent and predictable do you find FDA's current process for selecting national priority voucher recipients?

Question Title

* 4. If your company received a priority voucher, would it be ready for market launch in 2 months?

Question Title

* 5. Which drug development process would be easiest for your organization to scale up quickly?

Question Title

* 6. Can a thorough FDA review assessing safety and quality be completed in 1-2 months?

T